Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Metcela Inc. logo — Unleash the Cell Potential.

Metcela Inc.

Unleash the Cell Potential.

Founded 2016 Japan Japan 6 employees Series C Total: $2.83B Biotechnology, Health Care

General Information

Company Name Metcela Inc.
Founded Year 2016
Location Japan Japan
Employees 6
Industries Biotechnology, Health Care
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Metcela Inc.. To contact Metcela Inc., visit metcela.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Metcela Inc. compare?

A PDF of Metcela Inc. and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Metcela Inc. soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Metcela Inc.

Metcela Inc. is a Japan-based startup dedicated to revolutionizing heart failure treatment with their slogan "Unleash the Cell Potential." Founded in 2016, the company has a clear mission - to develop and commercialize an effective and reasonably priced therapy for heart failure utilizing specific fibroblast cells known as "VCF," obtained from the patient’s own heart. Their approach to heart failure therapy sets them apart from others in the industry; rather than simply replacing what is damaged, they aim to enhance the cells’ own ability to heal.

Their last investment, a significant ¥1.87B Series C investment on 28 June 2022, attracted attention from renowned investors including Sony Innovation Fund, CEJ Fund, Cyberdyne, Reazon Holdings, and Japan Lifeline.

Metcela operates within the Biotechnology and Health Care industries, addressing a critical global health issue while also targeting commercial success. Their innovative approach and recent funding make them an intriguing prospect for venture capitalists seeking impactful investments in the biotech sector.

Business keywords: cell therapy, heart failure, innovative therapy, clinical-stage biotech, cardiac fibroblast, VCF, treatment option, regenerative medicine, preclinical studies, patient-specific therapy, Japan-based startup, tissue repair, microenvironment modulation, personalized medicine

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Series C ¥1.87B 4
Sony Innovation Fund
Sony Innovation Fund, Cyberdyne +2
28 Jun 2022
Series B $12.70M 6
Eight Roads Ventures F-Prime Capital Sony Innovation Fund
Eight Roads Ventures, F-Prime Capital +4
04 Jan 2021
Series B ¥430.00M -
18 Mar 2020
Grant Undisclosed -
18 Sep 2018
Series A ¥520.00M -
30 Aug 2018

Metcela Inc. Alternatives & Competitors

View All Alternatives
Metcela Inc. vs
Heartseed Inc.
Heartseed Inc. Japan

Clinical-stage biotech company developing iPSC-derived highly purified ventricular cardiomyocytes fo...

IPO
20 employees
Biotechnology, Care Economy
Metcela Inc. vs
Noveome Biotherapeutics, Inc.
Noveome Biotherapeutics, Inc. United States

Transforming the way challenging diseases and conditions are treated.

Series E
25 employees
Biotechnology, Health Care
Metcela Inc. vs
BlueRock Therapeutics
BlueRock Therapeutics United States

Striving to transform the treatment of disease by harnessing the power of cell therapy

Acquired
478 employees
Biopharma, Biotechnology
View all alternatives

FAQ About Metcela Inc.

Unleash the Cell Potential.
Metcela Inc. was founded in 2016.
Metcela Inc. is headquartered in Japan.
Metcela Inc. operates in Biotechnology and Health Care. Its work centres on cell therapy, heart failure, innovative therapy and clinical-stage biotech.
Metcela Inc. has approximately 6 employees.
Metcela Inc. has completed 5 funding rounds, raising a total of $2.83B. The latest funding stage is Series C.
Top alternatives and competitors to Metcela Inc. include Heartseed Inc., Noveome Biotherapeutics, Inc., BlueRock Therapeutics, BreStem Therapeutics, Inc., Celixir. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Metcela Inc. and Heartseed Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Metcela Inc., https://bouncewatch.com/company/metcela-inc, updated 28 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout